Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Molecular and Cellular Biology|July 1, 2006
BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltratePrzemyslaw Juszczynski, Jeffery L Kutok, Cheng Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 3, 2012
MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20)Sang-Woo Kim, Kumaraguruparan Ramasamy, Hakim Bouamar, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesisDeepak Rai, Sang-Woo Kim, Morgan R McKeller, et al.
Leukemia|January 8, 2022
MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylasesAn-Ping Lin, Zhijun Qiu, Purushoth Ethiraj, et al.
Molecular Cancer Therapeutics|February 3, 2007
The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMAMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
Oncotarget|January 25, 2017
Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagyHongfeng Yuan, Meilan He, Fan Cheng, et al.
Leukemia|December 10, 2020
Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppressionBinu Sasi, Purushoth Ethiraj, Jamie Myers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2016
Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell MalignanciesKevin Kelly, Alex Mejia, Avvaru N Suhasini, et al.
Blood|August 9, 2003
Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinibKathryn Wilkinson, Elvira R P Velloso, Luiz Fernando Lopes, et al.
Biochemical Pharmacology|July 27, 2010
The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphomaMi-Ae Lyu, Bokyung Sung, Lawrence H Cheung, et al.
Pageof 5